Zacks.com announces that Dennis Slothower highlights the following stocks: SuperGen, Myogen, D R Horton, Gehl Co., and Florida Rock

Business Wire, August 4, 2005

CHICAGO -- Dennis Slothower, editor of the Stealth Stocks newsletter, says the Fed is stuck between a rock and an oil barrel. Take a look at SuperGen, Inc. (NASDAQ:SUPG), Myogen, Inc. (NASDAQ:MYOG), D R Horton (NYSE:DHI), Gehl Co. (NASDAQ:GEHL), and Florida Rock (NYSE:FRK). Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84

Highlights from the August 2nd Featured Expert column by Dennis Slothower include:

Stocks that Could Double in a Year

SuperGen, Inc. (NASDAQ:SUPG) engages in the development and commercialization of therapies for solid tumors, hematological malignancies, and blood disorders. Its principal products include Nipent (pentostatin) for injection, Orathecin (rubitecan) capsules, and Dacogen (decitabine) for injection.

Myogen, Inc. (NASDAQ:MYOG), a biopharmaceutical company, engages in the discovery, development, and commercialization of small-molecule therapeutics for the treatment of cardiovascular diseases. It markets an intravenous formulation of enoximone, Perfan I.V., in Europe for the treatment of acute decompensated heart failure.

From the Stealth Stocks Watch List...

D R Horton (NYSE:DHI), one of the largest homebuilders in the United States, builds high quality, single-family homes designed principally for the entry-level and move-up markets. The company also provides mortgage financing and title services.

Gehl Co. (NASDAQ:GEHL) designs, manufactures, sells and finances equipment used in light construction equipment and the agriculture equipment industries.

Florida Rock (NYSE:FRK) is principally engaged in the production and sale of ready mixed concrete and the mining, processing and sale of sand, gravel and crushed stone (construction aggregates). The Company also produces and sells concrete block and prestressed concrete and sells other building materials.

Read Dennis Slothower's commentary about the Fed's dilemma and learn about three more stocks that could double in a year by clicking: http://at.zacks.com/?id=85

About Zacks Featured Experts

Successful investing requires professional advice from knowledgeable experts who can help investors achieve their financial goals in good markets and improve their portfolios, especially in bad ones. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc.

Additional recommendations from Zacks.com Featured Experts are highlighted in the free investment newsletter, Profit from the Pros. Each issue highlights several Featured Experts in this free e-mail newsletter. Register for a free subscription to "Profit from the Pros" at: http://at.zacks.com/?id=86

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind Zacks work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. The goal is to unlock these pros' profitable insights for individual investors hard-pressed to find this valuable information in one source. A free subscription to "Profit from the Pros" weekly e-mail newsletter provides the best way to use these experts' insights for more profitable investing. Register now for a free subscription to the Profit from the Pros newsletter at http://at.zacks.com/?id=87

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.